Neutralizing Antibody Assay Development with High Drug and Target Tolerance to Support Clinical Development of an Anti-TFPI Therapeutic Monoclonal Antibody

被引:0
作者
Yuhong Xiang
Chuenlei Parng
Katrina Olson
Elena Seletskaia
Boris Gorovits
Darshana Jani
Teresa Caiazzo
Alison Joyce
Jean Donley
机构
[1] Pfizer Inc,
来源
The AAPS Journal | / 21卷
关键词
drug tolerance; hemophilia; target tolerance and neutralizing antibody; TFPI;
D O I
暂无
中图分类号
学科分类号
摘要
Immunogenicity is a major challenge for protein therapeutics which can potentially reduce drug efficacy and safety and is often being monitored by anti-drug antibody (ADA) and neutralizing antibody (NAb) assays. Circulating targets and residual drugs in matrices can have significant impacts on accuracy of results from ADA and NAb assays, and sufficient drug and target tolerance for these assays are necessary. Here, we report the development of a competitive ligand binding (CLB) NAb assay for an anti-TFPI (tissue factor pathway inhibitor) monoclonal antibody (PF-06741086) with high drug and target tolerance to support ongoing clinical studies. A double acid affinity capture elution approach was used to mitigate drug interference, and a robust target removal strategy was employed to enhance target tolerance. The validated NAb assay has sensitivity of 313 ng/mL, drug tolerance of 50 μg/mL, and target tolerance of 1200 ng/mL. A step-by-step tutorial of assay development is described in this manuscript along with the rationale for using a high drug/target tolerant NAb assay. The NAb assay cut point factor obtained was 0.78. Other assay performance characteristics, e.g., precision and selectivity, are also discussed. This validated method demonstrated a superior drug and target tolerance to warrant specific and precise characterization of the NAb responses in support of ongoing clinical studies.
引用
收藏
相关论文
共 118 条
[1]  
Buttel IC(2011)Taking immunogenicity assessment of therapeutic proteins to the next level Biologicals 39 100-109
[2]  
Chamberlain P(2008)Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products J Immunol Methods 333 1-9
[3]  
Chowers Y(2004)Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products J Immunol Methods 289 1-16
[4]  
Ehmann F(2008)Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products J Pharm Biomed Anal 48 1267-1281
[5]  
Greinacher A(2007)A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs Nat Biotechnol 25 555-561
[6]  
Jefferis R(2009)A bioactive drug quantitation based approach for the detection of anti-drug neutralizing antibodies in human serum J Immunol Methods 345 70-79
[7]  
Koren E(2017)Drug target interference in immunogenicity assays: recommendations and mitigation strategies AAPS J 19 1564-1575
[8]  
Smith HW(2018)A first-in-human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of PF-06741086, an anti-tissue factor pathway inhibitor mAb, in healthy volunteers J Thromb Haemost 16 1722-1731
[9]  
Shores E(1994)Heterogeneity of plasma tissue factor pathway inhibitor Blood Coagul Fibrinolysis 5 551-559
[10]  
Shankar G(2018)Translational pharmacokinetic/pharmacodynamic characterization and target-mediated drug disposition modeling of an anti-tissue factor pathway inhibitor antibody, PF-06741086 J Pharm Sci 107 1995-2004